Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants
The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma patients carrying a mutation in codon V600 of the BRAF gene exclusively. However, BRAF mutations outside the V600 codon may occur in a small percentage of melanomas. Although these rare variants may cause...
Main Authors: | Maria Chiara Scaini, Luisa Piccin, Davide Bassani, Antonio Scapinello, Stefania Pellegrini, Cristina Poggiana, Cristina Catoni, Debora Tonello, Jacopo Pigozzo, Luigi Dall’Olmo, Antonio Rosato, Stefano Moro, Vanna Chiarion-Sileni, Chiara Menin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/15/12285 |
Similar Items
-
Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
by: Cristina Catoni, et al.
Published: (2022-08-01) -
V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia
by: Neeraj Arora, et al.
Published: (2015-01-01) -
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
by: Valpione Sara, et al.
Published: (2015-03-01) -
Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
by: Ajay Bhargava, et al.
Published: (2016-02-01) -
A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance
by: Maria Chiara Scaini, et al.
Published: (2024-03-01)